

ASX RELEASE

27 December 2018

MediPharm Labs expands production capacity by 50 per cent

MMJ Group Holdings Limited (ASX: MMJ) ("MMJ") is pleased to attach a copy of a news release announcing that MediPharm Labs Inc ("MediPharm Labs") (TSX-V: LABS) has expanded its annual production capacity by 50 per cent.

MMJ owns approximately 4.4 million shares for a 4.5% shareholding and 2.9 million warrants (exercisable at CAD\$1.20 per share by October 2020) in MediPharm Labs.

Investor and Media Enquiries

Jason Conroy
Chief Executive Officer

About MMJ

MMJ Group Holdings Limited (ABN 91 601 236 417) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: <https://www.mmjgh.com.au/investors/>

Important Notice

This announcement contains reference to certain intentions, expectations, future plans, strategy and prospects of MMJ. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of MMJ may be influenced by a number of factors, many of which are outside the control of MMJ. No representation or warranty, express or implied, is made by MMJ, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause MMJ's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. MMJ does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in MMJ. This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). MMJ's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.



**MEDI PHARM LABS INCREASES ANNUAL PRODUCTION CAPACITY BY 50% UP TO 150,000KG;
POSITIONED TO MEET SIGNIFICANT DEMAND FOR PURIFIED CANNABIS CONCENTRATES AND OIL**

MediPharm Labs Maintains Largest Cannabis Extraction-Only Footprint in Canada

FOR IMMEDIATE RELEASE

December 24, 2018 - Toronto, Ontario - MediPharm Labs Corp. (TSXV: LABS) (the “**Company**” or “**MediPharm Labs**”) is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc. (“**MediPharm**”), has received approval from Health Canada to increase its current annual production capacity to process up to 150,000KG of dried cannabis, over five extraction lines, up from its standing processing capacity of up to 100,000KG over three extraction lines. The increase reflects the addition of a newly constructed extraction clean room, with new highly specialized and calibrated equipment, including two new extraction lines, that could produce up to 6,500KG of cannabis resin on an annual basis, the equivalent of approximately 9.7 million vape pens. With this expansion, MediPharm maintains its specialized leadership position with the largest extraction-only footprint in Canada, utilizing ISO designed clean rooms and critical environment laboratories, and proprietary methodologies.

“We are executing on our vision of global leadership in the extraction of purified cannabis concentrates, adding scale to our first-mover advantage in expertise and leadership,” said Pat McCutcheon, President and CEO of MediPharm Labs. “As we work towards completing our Phase 2 expansion, we are focused on the execution of our differentiated extraction-only business model that prioritizes the production of pharmaceutical-grade cannabis concentrates and isolates qualified for domestic distribution and, more importantly, large global scale distribution.”

As MediPharm continues to receive key regulatory approvals to increase its production capacity, the Company is making progress on its Phase 2 expansion plans that will see its annual production extraction capacity increase to upwards of 250,000KG of dried cannabis and is expected to be completed by Q2 2019.

Mr. McCutcheon concluded, “As we continue to invest in our growth, the timing couldn’t be better for our two new extraction lines to come onstream with Health Canada’s recent proposed regulations for expanded cannabis products, all of which are concentrate-based. 2019 will be a year focused on extraction in the cannabis industry and we are positioned to service the demand for active ingredient needed to produce beverages, edibles, vapables and topicals, all of which represent the fastest growing segments in the cannabis market.”

Pete Patterson, COO & Co-Founder, Vitalis Extraction Technology, commented on MediPharm’s latest production expansion capacity and acquisition of new Vitalis Extraction Equipment, “We are very impressed to see the rate at which MediPharm has been able to scale and execute on their plans. They



are setup to tackle some massive processing contracts that will help the Canadian markets meet the upcoming demand for concentrates.”



MediPharm Labs Co-founders, Keith Strachan, Vice President (L) and Pat McCutcheon, President and CEO (R) are pictured in the company's newly licensed processing room featuring two new industrial-scale extraction lines utilizing new Vitalis Extraction Technology equipment.

Click on link to download high resolution photos and video of the Extraction Clean Room:

https://www.dropbox.com/sh/agmtfp9228975mk/AAB3woAgATTUH9ScxcvzkF_Ga?dl=0

About Vitalis Extraction Technology

Vitalis Extraction Technology Inc.© (Vitalis) is a privately-owned, Kelowna-based engineering and manufacturing company, producing industrial supercritical CO2 extraction systems for the cannabis industry. The company's core focus on innovation and design has vaulted it to the forefront of the market. Renowned for their reliability, scalability, and continuous operation, Vitalis systems are designed and manufactured in its ASME-certified facility in accordance with ASME and CSA Standards for Boiler, Pressure Vessel and Pressure Piping. The vessels are stamped with a CRN and NB registration number confirming that the vessels meet both US and Canadian code requirements. With systems on three continents, Vitalis has the most deployments of industrial CO2 supercritical extractors into the cannabis industry. In 2017 & 2018, Vitalis has won Top Extraction Equipment at the Canadian Cannabis Awards, and several British Columbia-based awards including Manufacturer of the Year and Technology Innovator of the Year. For more information, visit www.vitaliset.com.

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the Access



to Cannabis for Medical Purposes Regulations (ACMPR) without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from its cGMP (current Good Manufacturing Practices) and ISO standard-built clean rooms and critical environments laboratory, allows MediPharm Labs to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil with a competitive advantage. MediPharm Labs is research-driven and focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm Labs provides B2B contract processing of cannabis to Canadian authorized licensed producers and appropriate international growers, supplying integrity-assured cannabis oil to qualified companies for sale under their own brand. In addition, MediPharm Labs will supply raw materials, formulations, processing and packaging for the creation of ready-to-sell advanced derivative products. MediPharm Labs was awarded **Start-up of the Year** at the recent Canadian Cannabis Awards hosted by Lift & Co.

Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.

For further information, please contact:

Laura Lepore, Vice President, Investor Relations & Communications

Telephone: 705-719-7425 ext 216

Email: investors@medipharmlabs.com

Website: www.medipharmlabs.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, expected product offerings and product



equivalents, future capacity expansion, expected GMP certification and the establishment of operations in Australia. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; and the delay or failure to receive regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.